[go: up one dir, main page]

LV10186B - The pharmacological use of certain cystine derivatives - Google Patents

The pharmacological use of certain cystine derivatives Download PDF

Info

Publication number
LV10186B
LV10186B LVP-93-1017A LV931017A LV10186B LV 10186 B LV10186 B LV 10186B LV 931017 A LV931017 A LV 931017A LV 10186 B LV10186 B LV 10186B
Authority
LV
Latvia
Prior art keywords
diacetylcystine
diisovalerylcystine
dimethyl ester
physiologically acceptable
dicaprilylcystine
Prior art date
Application number
LVP-93-1017A
Other languages
English (en)
Latvian (lv)
Other versions
LV10186A (lv
Inventor
Andersson Carl-Magnu Alexander
Bergstrand Sten Hakan Axe Magn
Hallberg Anders Rudolf
Sarnstrand Bengt Olof
Tunek Per Anders Sigvard
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9002067A external-priority patent/SE9002067D0/xx
Priority claimed from SE9002275A external-priority patent/SE9002275D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of LV10186A publication Critical patent/LV10186A/xx
Publication of LV10186B publication Critical patent/LV10186B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LVP-93-1017A 1990-06-08 1993-08-06 The pharmacological use of certain cystine derivatives LV10186B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9002067A SE9002067D0 (sv) 1990-06-08 1990-06-08 The pharmacological use of certain cystine derivatives
SE9002275A SE9002275D0 (sv) 1990-06-28 1990-06-28 Novel 3,3'-dithiobis(propionic acids)
PCT/SE1991/000388 WO1991018594A1 (en) 1990-06-08 1991-06-03 The pharmacological use of certain cystine derivatives

Publications (2)

Publication Number Publication Date
LV10186A LV10186A (lv) 1994-10-20
LV10186B true LV10186B (en) 1995-08-20

Family

ID=26660796

Family Applications (2)

Application Number Title Priority Date Filing Date
LVP-93-1017A LV10186B (en) 1990-06-08 1993-08-06 The pharmacological use of certain cystine derivatives
LVP-97-219A LV11985B (en) 1990-06-08 1997-10-30 PHARMACOLOGICAL USE OF CERTAIN DERIVATIVES

Family Applications After (1)

Application Number Title Priority Date Filing Date
LVP-97-219A LV11985B (en) 1990-06-08 1997-10-30 PHARMACOLOGICAL USE OF CERTAIN DERIVATIVES

Country Status (20)

Country Link
US (2) US5441976A (no)
EP (1) EP0532595B1 (no)
JP (1) JP3204320B2 (no)
KR (1) KR100236253B1 (no)
AT (1) ATE144705T1 (no)
AU (1) AU652946B2 (no)
CA (1) CA2083274C (no)
DE (1) DE69122961T2 (no)
DK (1) DK0532595T3 (no)
HK (1) HK62597A (no)
HU (1) HU215920B (no)
IE (1) IE80754B1 (no)
IL (1) IL98310A (no)
LV (2) LV10186B (no)
NO (1) NO924723D0 (no)
NZ (1) NZ247658A (no)
PT (1) PT97905B (no)
RU (1) RU2119793C1 (no)
SG (1) SG49736A1 (no)
WO (1) WO1991018594A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9018994D0 (en) * 1990-08-31 1990-10-17 Secr Defence Toxic agent protective compounds
US5889050A (en) * 1991-06-21 1999-03-30 Astra Aktiebolag 3,3'-dithiobis (propionic acids) and esters thereof
SE9103572D0 (sv) * 1991-11-29 1991-11-29 Astra Ab Organic salts of n,n'-diacetyl cystine
JP2947044B2 (ja) * 1993-01-27 1999-09-13 味の素株式会社 免疫不全症候群治療の補助療法剤
DE4329857C2 (de) * 1993-09-03 1995-08-24 Deutsches Krebsforsch Verbindung zur Stärkung des Immunsystems und von Immunreaktionen
SE9500897D0 (sv) * 1995-03-14 1995-03-14 Astra Ab The pharmacological use of certain cystine derivatives
SE9501067D0 (sv) * 1995-03-24 1995-03-24 Astra Ab New peptides
SE9602262D0 (sv) * 1996-06-06 1996-06-06 Astra Ab New use of derivatives of cystine
US20030203006A1 (en) * 1997-10-29 2003-10-30 Ajinomoto Co. Inc. Immunomodulator
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
CN100453531C (zh) 1998-10-09 2009-01-21 味之素株式会社 半胱氨酸衍生物
EP1004302A3 (en) * 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
SE9900438D0 (sv) * 1999-02-10 1999-02-10 Astra Ab The pharmacological use of certian cystine derivatives
JP3988014B2 (ja) * 2000-02-02 2007-10-10 味の素株式会社 ウイルス感染症予防剤
US8048451B2 (en) 2000-11-30 2011-11-01 Vectura Limited Pharmaceutical compositions for inhalation
SE518784C2 (sv) * 2000-12-27 2002-11-19 Nactilus Ab "N-Acetyl-L-cystein med kompositioner för behandling av neoplasier"
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
DE102004043055B4 (de) 2004-09-06 2009-04-02 Siemens Ag Führungsvorrichtung zur Führung eines bewegbaren Maschinenelementes einer Maschine
AU2007325972A1 (en) * 2006-10-03 2008-06-05 Galleon Pharmaceuticals, Inc. S-nitrosothiol compounds and related derivatives
CA2866037C (en) * 2007-04-23 2017-05-16 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7829709B1 (en) 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
EP2252596B1 (en) * 2008-02-07 2016-12-28 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
JP6458809B2 (ja) 2014-04-25 2019-01-30 味の素株式会社 免疫賦活剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR8205M (no) * 1968-12-20 1970-09-14
US3878305A (en) * 1972-05-25 1975-04-15 Procter & Gamble Fortification of foodstuffs with n-acyl derivatives of sulphur-containing l-amino acids
US3952115A (en) * 1975-04-02 1976-04-20 The Procter & Gamble Company Fortification of foodstuffs with N-acyl derivatives of sulfur-containing L-amino acid esters
GB2097256B (en) * 1981-04-02 1985-05-30 Morelle Jean V Compositions containing n-butyryl alphaaminoacids
FR2503151A1 (fr) * 1981-04-02 1982-10-08 Morelle Jean Butyryminoacides soufres. mode de preparation. emploi comme element keratogenique chez l'homme et l'animal et comme agent de fertilisation chez les vegetaux
US4724239A (en) * 1985-09-16 1988-02-09 Morgan Lee R Method of treating chemical ulcers with N,N'-diacetylcystine, N-acetyl homocysteine and N-acetyl cysteine
US4827016A (en) * 1985-09-16 1989-05-02 Morgan Lee R Method and compounds for reducing dermal inflammations
US4708965A (en) * 1985-09-16 1987-11-24 Morgan Lee R Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
IT1249650B (it) * 1991-05-29 1995-03-09 Poli Ind Chimica Spa N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico

Also Published As

Publication number Publication date
PT97905B (pt) 1998-10-30
HU9203871D0 (en) 1993-03-29
RU2119793C1 (ru) 1998-10-10
DE69122961D1 (de) 1996-12-05
WO1991018594A1 (en) 1991-12-12
DK0532595T3 (da) 1997-04-07
HUT70055A (en) 1995-09-28
EP0532595B1 (en) 1996-10-30
CA2083274C (en) 2002-05-28
US5780508A (en) 1998-07-14
NZ247658A (en) 2000-07-28
LV10186A (lv) 1994-10-20
IE80754B1 (en) 1999-01-13
HU215920B (hu) 1999-03-29
DE69122961T2 (de) 1997-03-13
LV11985B (en) 1998-06-20
AU652946B2 (en) 1994-09-15
JPH05507705A (ja) 1993-11-04
NO924723L (no) 1992-12-07
JP3204320B2 (ja) 2001-09-04
PT97905A (pt) 1992-03-31
NO924723D0 (no) 1992-12-07
EP0532595A1 (en) 1993-03-24
HK62597A (en) 1997-05-16
US5441976A (en) 1995-08-15
ATE144705T1 (de) 1996-11-15
IL98310A (en) 1996-08-04
LV11985A (lv) 1998-03-20
AU8094191A (en) 1991-12-31
CA2083274A1 (en) 1991-12-09
IE911945A1 (en) 1991-12-18
SG49736A1 (en) 1998-06-15
IL98310A0 (en) 1992-06-21
KR100236253B1 (ko) 1999-12-15

Similar Documents

Publication Publication Date Title
EP0532595B1 (en) The pharmacological use of certain cystine derivatives
AP350A (en) Organic salts of N,N-Diacetyl cystine.
JP2001508804A (ja) 代謝を増強し酸化ストレスを防止するための食物組成物
US11040022B2 (en) Compositions and methods for pain relief
EP2696864A1 (en) Therapeutic compounds
DE3907649A1 (de) Arzneimittel, geeignet bei der bekaempfung von viren und der immunstimulierung
EP0516594A1 (en) L-carnitine derivatives as therapeutical agents for treating myopathies and neuronal degeneration and for inhibiting proteolysis
US7169813B2 (en) 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer
PL165344B1 (pl) Sposób wytwarzania nowych pochodnych kwasu 3,3’-ditiobispropionowego PL PL PL PL
DE3907688A1 (de) Salze von ungesaettigten fettsaeuren mit aminosaeuren, verfahren zu ihrer herstellung und diese enthaltende arzneimittel sowie die verwendung der ersteren
AU2013202114B2 (en) Acne treatment
EP0727207A1 (en) The pharmacological use of certain cystine derivatives
CA2193396A1 (en) A pharmaceutical composition for the prevention and/or treatment of viral infections and optionally inflammations as well as a method for the treatment thereof
NZ238306A (en) Pharmaceutical compositions containing certain cystine derivatives.
JP4255138B2 (ja) 脳疾患治療剤
US11479579B2 (en) Therapeutic compounds and methods
SK13902000A3 (sk) Trisulfidy, spôsob ich prípravy a farmaceuticky prijateľná kompozícia, ktorá ich obsahuje
AU2008200720B2 (en) Geranyl compounds
IT9021967A1 (it) Composizioni farmaceutiche contenenti acido 2-(2-pirrolidon-5- carbonilamido)-3mercaptopropionico, per il trattamento di malattie connesse ad una carenza di glutatione
CS209860B2 (cs) Způsob výroby nových derivátů aminokyselin